<DOC>
	<DOCNO>NCT00453050</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , imiquimod , may stimulate immune system different way stop tumor cell grow . Laser therapy use light kill tumor cell . Giving imiquimod together laser therapy may kill tumor cell . PURPOSE : This phase I trial study side effect imiquimod laser therapy without green dye treat patient stage III stage IV melanoma spread part skin .</brief_summary>
	<brief_title>Imiquimod Laser Therapy With Without Green Dye Treating Patients With Stage III Stage IV Melanoma That Has Spread Other Parts Skin</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity situ photoimmunotherapy comprise imiquimod infrared laser therapy without indocyanine green patient stage III IV melanoma cutaneous metastasis . - Determine complete systemic local response rate patient treated regimen . Secondary - Determine effect treatment immunologic parameter patient . OUTLINE : This prospective , open-label , pilot study . Patients undergo situ photoimmunotherapy ( ISPI ) comprise topical imiquimod twice daily day 1-42 infrared laser therapy ( without indocyanine green ) day 14 28 . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Blood collect baseline , prior ISPI , 24 hour ISPI , week 6 . Samples examine cytokine response , CD8 T-cell activation regulatory T-cell assay ( flow cytometry ) , antibody response ( western blot ) . After completion study treatment , patient follow monthly 3 month every 3 month 2 year . PROJECTED ACCRUAL : A total 70 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma meeting follow criterion : Stage III IV disease Stage IV disease without observable , surgically unresectable metastasis beyond immediate treatment site allow Presence 1 cutaneous metastasis ≤ 3 cm size Diffuse area tumor involvement use qualify study area involve primarily epidermis and/or dermis less 3 cm thickness No uncontrolled brain metastasis Treated brain metastasis stable 3 month allow investigator 's discretion PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 4 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study completion No known allergy drug use study treatment No unstable medical illness Not immunosuppressed Patients immunosuppressed due disease ( e.g. , HIV positive ) allow PRIOR CONCURRENT THERAPY : No systemic steroid immunosuppressive medication within past month No chemotherapy within past 4 week No radiotherapy treatment site within past 4 week Palliative radiotherapy sit cutaneous treatment assessment sit allow No concurrent immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>skin metastasis</keyword>
</DOC>